Skip to Content
Merck
  • LINC00324 facilitates cell proliferation through competing for miR‑214‑5p in immature ovarian teratocarcinoma.

LINC00324 facilitates cell proliferation through competing for miR‑214‑5p in immature ovarian teratocarcinoma.

International journal of molecular medicine (2021-01-09)
Meiling Chen, Min Zhang, Ling Xie, Sanshan Wu, Yuanyuan Zhong
ABSTRACT

Immature ovarian teratocarcinoma (IOT) is a rare and malignant type of ovarian teratoma, and the molecular mechanisms underlying the pathogenesis and malignant phenotype of IOT remain uncharacterized. The present study examined a long non‑coding RNA (lncRNA), long‑chain intergenic non‑coding RNA324 (LINC00324), which may serve a crucial role in pathogenesis of IOT. According to the results, LINC00324 was upregulated in IOT tissues and cells, as determined by reverse transcription‑quantitative PCR, and its depletion impaired cell proliferation ability and improved cell apoptosis ability in IOT. Furthermore, LINC00324 acted as a miR‑214‑5p sponge to derepress cyclin dependent kinase 6 (CDK6), cyclin D1 (CCND1), murine double minute homolog 2 (MDM2), and mouse double minute 4 (MDM4) expression, thus increasing IOT cell proliferation and repressing apoptosis. Taken together, these results demonstrated that LINC00324 could serve as a competing endogenous RNA to facilitate IOT cell proliferation by regulation of miR‑214‑5p‑CDK6/CCND1/MDM2/MDM4 network, which possibly provide a novel therapeutic target for IOT.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Ago2 Antibody, clone 11A9, clone 11A9, from rat